SMARCA4-DEFICIENT TUMOR

Clinical trials for SMARCA4-DEFICIENT TUMOR explained in plain language.

Never miss a new study

Get alerted when new SMARCA4-DEFICIENT TUMOR trials appear

Sign up with your email to follow new studies for SMARCA4-DEFICIENT TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 2

New cancer drug trial targets specific genetic weakness

Disease control Recruiting now

This study is testing a new drug called LY4050784 for people with advanced solid tumors that have a specific genetic change called a SMARCA4/BRG1 alteration. The main goals are to find a safe dose of the drug, given alone or with other cancer treatments, and to see if it helps sh…

Matched conditions: SMARCA4-DEFICIENT TUMOR

Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

SMARCA4-DEFICIENT TUMOR

Get alerted when new SMARCA4-DEFICIENT TUMOR trials appear

New cancer drug trial targets specific genetic weakness